Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: somatostatin receptor agonist therapeutics - Crinetics Pharmaceuticals

Next Previous
Drug Profile

Research programme: somatostatin receptor agonist therapeutics - Crinetics Pharmaceuticals

Alternative Names: CRN02481

Latest Information Update: 13 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crinetics Pharmaceuticals
  • Class Antihypoglycaemics; Small molecules
  • Mechanism of Action Somatostatin receptor 5 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hyperinsulinaemia

Most Recent Events

  • 13 May 2020 9292080 - Info already covered
  • 09 Mar 2020 Preclinical trials in Hyperinsulinaemia in USA (PO) before March 2020
  • 05 Aug 2019 Crinetics Pharmaceuticals receives SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institutes of Health (NIH) for CRN 02481 development in Hyperinsulinaemia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top